Drug Price Negotiations: Which 10 Medicare Part D Drugs Just Got Cheaper?

The “First 10” Negotiated List (2026)

The Centers for Medicare & Medicaid Services (CMS) selected these drugs based on high total spending and the absence of generic competition.

Why This Matters for Your Wallet

Even if you have a fixed copay, these negotiations lower the overall cost of the plan.

• Slower Deductible Climb: Because the “list price” of these drugs is now lower, you will move through your deductible and initial coverage phases more slowly, keeping you in the low-cost zone longer.
• The $2,100 Safety Net: These lower prices, combined with the new 2026 $2,100 Out-of-Pocket Cap, mean that seniors with multiple chronic conditions could save thousands of dollars this year.

Guaranteed Formulary Placement

Under 2026 federal rules, Medicare Part D plans must include these 10 negotiated drugs on their formularies. This prevents insurance companies from “dropping” a drug just because the profit margin decreased due to negotiation.

What’s Next? (The 2027 & 2028 Waves)

The 2026 list is just the beginning.

• 2027: Negotiated prices for 15 more Part D drugs (including popular GLP-1s like Ozempic and Wegovy) are already being finalized for next year.
• 2028: CMS has already selected another 15 drugs (including physician-administered Part B drugs like Xolair and Botox) for the 2028 cycle.

Sources & References (May 2026)

• Source: CMS.gov – Medicare Drug Price Negotiation Program: Selected Drugs and Negotiated Prices
• Source: KFF – Key Facts About Medicare Drug Price Negotiation (Updated March 2026)
• Source: ASPE – Medicare Drug Price Negotiation Program: Negotiated Prices vs. List Prices
• Source: DLA Piper – Keeping Watch on Medicare: 2026 Maximum Fair Prices for Ten Selected Drugs